Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Leukemia, Myelocytic, Acute
Interventions
BIOLOGICAL

CD34+ selection with CliniMACS device

CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ \>5 x 10\*6/kg and CD3+ \< 1 x 10\*5/kg

Trial Locations (8)

10021

Memorial Sloan-Kettering Cancer Center, New York

19104

University of Pennsylvania Cancer Center, Philadelphia

43210

Ohio State/Arthur G. James Cancer Hospital, Columbus

44106

University Hospitals of Cleveland/Case Western, Cleveland

53211

Medical College of Wisconsin, Milwaukee

91010

City of Hope National Medical Center, Duarte

94143

University of California, San Francisco, San Francisco

02114

Dana Farber Cancer Institute/Brigham & Women's Hospital, Boston

All Listed Sponsors
collaborator

Blood and Marrow Transplant Clinical Trials Network

NETWORK

collaborator

National Cancer Institute (NCI)

NIH

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00201240 - Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) | Biotech Hunter | Biotech Hunter